Hong Kong stock exchange data reveals that on March 18, a shareholder of CLOUDBREAK-B deposited shares with Construction Asia. The deposited holdings are valued at HK$194 million, representing 11.23% of the company's shares. On February 16, CLOUDBREAK-B announced that its wholly-owned U.S. subsidiary, ADS Therapeutics LLC, had completed the review period for the Investigational New Drug application submitted to the U.S. Food and Drug Administration for CBT-199. CBT-199 is a potential best-in-class ophthalmic drug candidate developed by the group, with the application submitted on December 12, 2025. As the FDA did not issue any clinical hold order, the IND is now effective, and the clinical trial is deemed safe to proceed.